Business Context and Reporting Period
Company: Milestone Pharmaceuticals Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: July 29, 2020
Reporting Period: Event date of July 29, 2020.
Context: The Company, an emerging growth company incorporated in Québec, entered into a material definitive agreement to facilitate the sale of its common shares.
Key Financial Metrics
This filing does not report operational financial metrics such as revenue, profit, cash flow, margins, or debt levels. The filing focuses exclusively on a capital raising mechanism.
- Maximum Aggregate Sales Price: Up to $50,000,000.
- Commission Rate: 3.0% of aggregate gross sales proceeds.
- Legal Expense Reimbursement Cap: $65,000.
- Trading Symbol: MIST (Nasdaq Global Select Market).
Material Changes
The material change reported is the execution of an Open Market Sale Agreement (the "Agreement") with Jefferies LLC, acting as sales agent. Under this agreement, the Company may issue and sell common shares from time to time via "at the market" offerings. The Company is not obligated to sell any shares under this agreement.
Guidance, Outlook, and Risks
Management Commentary: The Company retains discretion over the timing, price, and size of any sales through Jefferies. The offering will terminate upon the sale of all shares subject to the agreement or earlier termination per the agreement's terms.
Risks and Contingencies:
- Dilution: Issuance of new shares may dilute existing shareholders.
- Market Conditions: Sales are subject to market conditions and the Company's instructions.
- Legal Compliance: The report explicitly states it does not constitute an offer to sell in jurisdictions where such an offer would be unlawful prior to registration.
Investor Verification Checklist
- Verify the current share price and potential dilution impact of a $50 million offering.
- Review the full text of the Open Market Sale Agreement (Exhibit 10.1) for specific termination clauses and conditions.
- Confirm the status of the underlying shelf registration statement (Form S-3, File No. 333-239318).
- Monitor future filings for actual sales volumes and proceeds generated under this agreement.